China's diabetes drugs may be in short supply by 2030

[industry trends of China Pharmaceutical network] diabetes mellitus is an endocrine and metabolic disease with high blood glucose caused by insufficient insulin secretion Data shows that by 2018, the number of diabetic patients in the world has exceeded 450 million, while China, as a high incidence area of diabetes, currently, the number of diabetic patients in China has exceeded 120 million The industry said that because of the irreversibility of diabetes and the increasing incidence rate in recent years, it is estimated that by 2030, the situation of diabetes drugs in China will be in short supply I have learned that there are many kinds of diabetes drugs on the market, and each drug has different instructions Among them, the first choice of type 2 diabetes is metformin, monotherapy or combination therapy It has good effects, such as improving insulin sensitivity, reducing the output of liver sugar, reducing the incidence rate of cardiovascular diseases, and assisting weight loss When the side effects of metformin are too large, the industry suggests that patients can choose α - glucosidase inhibitor, sglt-2 inhibitor, DPP-4 inhibitor, insulin secretion promoting agent and other drugs If the above drugs are used alone, the patient's blood sugar is still not up to the standard, so they need to enter the dual therapy Generally, metformin + oral drugs, or metformin + injection drugs are used for sugar control treatment In addition, triple therapy is to select the above three different mechanisms of hypoglycemic drugs combined use However, if the blood glucose control is still not up to the standard after triple therapy, it is necessary to adjust the treatment plan to multiple insulin treatment and stop insulin secretagogue Recently, many foreign pharmaceutical companies have targeted the diabetes market in China For example, tenelia, a type 2 diabetes drug, will be launched in China It is reported that tenelia is the first DPP-4 inhibitor from Japan, which was listed in Japan in 2012 and gradually in South Korea and other countries Clinical research shows that the standard rate of single drug treatment of tenelia is 70%, and HbA1c (glycosylated hemoglobin) is reduced by 0.82% In addition, compared with placebo, tigletin treatment did not increase the risk of hypoglycemia and other adverse reactions Recently, Servier China and Tianbian Mitsubishi group, which develops tenelia, have signed an agreement in Beijing to promote the drug in China As for the specific time when tenelia was approved for listing, Tianbian Mitsubishi said it would make the drug go to the Chinese market as soon as possible In addition, with the development of the consistency evaluation of generic drugs, and the continuous improvement of R & D capability, process capability and quality management capability of Chinese pharmaceutical enterprises, the pharmaceutical technology in China is expected to break out in the next few years For example, in February this year, Qingdao Baiyang Pharmaceutical Co., Ltd received the good news of great breakthrough in generic pharmaceutical technology The new metformin drug Neda, which uses osmotic pump controlled-release technology, was approved and listed by the FDA in the United States, bringing good news to the patients with type 2 diabetes, especially those with obesity and hyperinsulinemia It is reported that Nida's first batch of drugs will be delivered to the U.S market It is expected that Nida will be approved for marketing in China within this year, and it is expected to become the first osmotic pump controlled-release metformin product in China It is understood that the osmotic pump controlled release technology adopted by Baiyang pharmaceutical metformin hydrochloride (NIDA) can make the drug release in the body at a constant speed, and the blood concentration of the drug is more stable While reducing gastrointestinal tract stimulation and toxic side effects, it also reduces the number of times of taking medicine for diabetic patients, and increases the drug compliance of patients Its active ingredients, route of administration, dosage form, use conditions and bioequivalence are consistent with the original research drug, and the price of the original research drug in China may only be 1% of the market price of the original research drug in the United States in the future Diabetes is an illness that can not be eradicated Reducing or stopping drugs will have an impact on patients Therefore, the incidence rate of diabetes in China is increasing year by year, and the demand for diabetes drugs and treatment programs will also expand.